GenixPharmaceucticals Corporation (GENX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GenixPharmaceucticals Corporation (GENX) has a cash flow conversion efficiency ratio of 0.011x as of April 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-16.30K ≈ $-11.79K USD) by net assets (CA$-1.55 Million ≈ $-1.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GENX equity financing ratio to measure how much of total assets are equity-financed.
GenixPharmaceucticals Corporation - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how GenixPharmaceucticals Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check GenixPharmaceucticals Corporation cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
GenixPharmaceucticals Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GenixPharmaceucticals Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Panthera Resources PLC
LSE:PAT
|
-0.413x |
|
IMAGE POWER S.A. ZY -10
F:7UQ
|
0.628x |
|
Procook Group PLC
LSE:PROC
|
0.073x |
|
Agronomics Ltd
LSE:ANIC
|
-0.005x |
|
Calnex Solutions Plc
LSE:CLX
|
0.111x |
|
Real Estate Investors PLC
LSE:RLE
|
0.018x |
|
Crystal Amber Fund Limited
LSE:CRS
|
-0.003x |
|
Made Tech Group PLC
LSE:MTEC
|
0.110x |
Annual Cash Flow Conversion Efficiency for GenixPharmaceucticals Corporation (2015–2025)
The table below shows the annual cash flow conversion efficiency of GenixPharmaceucticals Corporation from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of GenixPharmaceucticals Corporation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | CA$-1.42 Million ≈ $-1.03 Million |
CA$-124.07K ≈ $-89.75K |
0.087x | -44.79% |
| 2024-10-31 | CA$-1.18 Million ≈ $-855.91K |
CA$-187.34K ≈ $-135.52K |
0.158x | -18.39% |
| 2023-10-31 | CA$-1.14 Million ≈ $-822.75K |
CA$-220.67K ≈ $-159.63K |
0.194x | +382.67% |
| 2022-10-31 | CA$3.20 Million ≈ $2.31 Million |
CA$-219.58K ≈ $-158.84K |
-0.069x | +35.67% |
| 2021-10-31 | CA$4.01 Million ≈ $2.90 Million |
CA$-428.31K ≈ $-309.83K |
-0.107x | -165.74% |
| 2020-10-31 | CA$4.86 Million ≈ $3.51 Million |
CA$-195.03K ≈ $-141.08K |
-0.040x | -102.89% |
| 2019-10-31 | CA$-42.13K ≈ $-30.48K |
CA$-58.55K ≈ $-42.35K |
1.390x | +398.33% |
| 2018-10-31 | CA$122.57K ≈ $88.66K |
CA$34.18K ≈ $24.72K |
0.279x | +460.73% |
| 2017-10-31 | CA$120.97K ≈ $87.51K |
CA$-9.35K ≈ $-6.76K |
-0.077x | +82.00% |
| 2016-10-31 | CA$384.43K ≈ $278.09K |
CA$-165.07K ≈ $-119.41K |
-0.429x | +51.91% |
| 2015-10-31 | CA$506.89K ≈ $366.67K |
CA$-452.55K ≈ $-327.37K |
-0.893x | -- |
About GenixPharmaceucticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral,… Read more